Tag Archives: technology

Light My Fire…

This past quarter 3,336 companies raised over $267 billion which eclipsed every prior full year, save two of them (2021 and 2025), underscoring the extraordinary enthusiasm among venture capitalists for anything AI. Notwithstanding the frothy valuations and capital intensity of AI platform companies, one of the pleasant knock-on effects might be the surge in new company formation. While AI adoption may also foretell dramatic job losses, it does strongly suggest that with the proliferation of these capabilities it will be easier to be an entrepreneur. 

New Business Applications

Source: Apollo

Just over the past twelve months the number of new business applications spiked from ~100,000 per month to ~140,000 per month (right hand axis, above). Notably, the onset of the pandemic and its short-lived recession six years ago pushed many to become entrepreneurial out of necessity. The forces are different now and the impact less dire and immediate, but the result may be similar.

Obviously, it is a complicated, confusing time, made more so by conflicting social media posts almost hourly from the Administration and the on-again, off-again war with Iran. While making short-term investment decisions is fraught with extreme risks now, there are important signals to watch. Unemployment rates are manageable and in line with a good economy. Inflation is only slightly elevated, even in light of the body blows delivered to the economy over the past year. Somewhat surprising, the NASDAQ Index is trading at levels that are below historic averages, which for many may be counterintuitive given frothy private market valuation multiples.

NASDAQ 100 Forward P/E Ratio

Source: Citadel Securities

The employment picture is more nuanced, exacerbated by the hostility directed at immigration. Currently the level of job vacancies is largely balanced with the level of unemployment. Early in the pandemic the number of unfilled jobs spiked labor inflation rates. The prospect of job losses, perhaps due to impact of AI-driven replacement capabilities, may serve to mute the impact on inflation. In fact, according to the Bureau of Labor Statistics the U.S. economy only added a net of 181,000 jobs in all of 2025. An analysis by Fortune estimated that the U.S. healthcare sector alone created 693,000 new jobs in 2025, and that were it not for healthcare, overall job growth would have been negative.

Vacancy to Unemployment Ratio

Source: Bureau of Labor Statistics, BofA Global Research

More specifically, the labor market for IT positions has turned decidedly negative. In March employment in the technology sector declined by 24% from March 2025, according to data from Challenger, Gray & Christmas, with an overall net IT job loss of 52,000 in 1Q26. Bureau of Labor Statistics data had IT unemployment at 3.9% at the end of 1Q26, up from 3.1% in 1Q25. Bank of America data highlights the rotation from payroll costs to increased expenditures on technology among U.S. small businesses – technology replacing labor.

 Payments to Payroll vs. Technology Services

Source: Bank of America (percent change, 3-month rolling average)

The level of venture capital investment this past quarter was historic by any measure. The five largest investments totaled $195.6 billion of the $267.2 billion (73% of the total) and yet was only 0.1% of the deals closed. While one might credibly argue that the $122 billion OpenAI round is not a venture capital deal, undeniably the AI companies simply dominated this past quarter, capturing nearly 89% of all invested capital and represented 43% of all companies. Notwithstanding a level of “AI-washing” with how companies now describe themselves, Pitchbook estimated that in 1Q26 AI companies accounted for 45% of the $9.5 trillion value held by venture capital funds.

This level of activity somewhat obfuscates the continued decline in the absolute number of investments made at each stage, although the proportion of larger and later stage rounds continued to increase. This rotation highlights the concentration of capital behind fewer companies as well as the dramatic increase in late-stage company valuations. Across all sectors late-stage rounds averaged $47.6 million ($44.0 billion invested across 925 deals) in 1Q26 as compared to $24.8 million in 4Q25. 

Quarterly Venture Capital Investment Activity

Source: Pitchbook

This is not just a U.S. phenomenon although the U.S. market carries much of the water. Globally, 1Q26 venture capital investment activity touched $300 billion in nearly 6,000 companies, according to Crunchbase data. Of this amount, $242 billion was invested in AI companies.

Global Venture Capital Investment Activity

Source: Crunchbase

An obvious implication of this level of concentrated investment activity is the restocking of the unicorn herd. In 1Q26 another 66 unicorns were minted bringing the total to 912 companies valued at $5.8 trillion based on the post-money valuations of the last round according to Pitchbook. While many choose to stay private and independent longer, many other scaled companies continue to struggle to exit.

This shines a bright light on a cruel irony: rarely has such a new technology generated so much investor interest and created so many valuable companies and yet exit activity remains frustratingly elusive. Notwithstanding that 1Q26 looks like a blow-out quarter for exits, the $347 billion includes the $250 billion combination of SpaceX with xAI, which was not really a liquidity event. Setting that transaction aside, the $97 billion of remaining exit activity continues the modest recovery seen over the last several quarters in total exits. The average transaction value (ex-xAI) in 1Q26 was nearly $300 million, which is appreciably greater than the $230 million in 4Q25.

Quarterly Exit Activity

Source: Pitchbook

Analysts are calling for the SpaceX IPO this year to be valued over $1.5 trillion (~55x 2026 revenues) – crazy for a company that was last valued at $350 billion just over a year ago. This event could well be followed by IPOs at OpenAI and Anthropic, among several other very significant private venture-backed companies. Much could still derail any or all of these liquidity events but there is cautious optimism that investors will start to see dramatic distributions unlocked later this year. Obviously, it will be unevenly felt at first but one should expect to see that fundraising prospects for the long tail of venture capital firms should improve.

Secondary transactions continue to come of age as a possible path to liquidity. Last year secondaries totaled $240 billion across all private asset classes according to Jeffries, which was a six-fold increase from 2015. To provide some context, the broader private capital industry is estimated to be $24 trillion.

Fundraising in 1Q26 totaled $47.8 billion across 172 funds (average fund size $278 million), which compares nicely to the $66.7 billion across 626 funds (average fund size of $107 million) in all of 2025. What this masks is again the extreme concentration of success for just several firms in 1Q26. In fact, just six funds accounted for $36.4 billion or more than three-quarters of the capital raised. Exclusive of these top six funds, the average fund size was $69 million. Of all the funds raised in 1Q26, only 29 were raised by first-time fund managers. Shockingly, the median fund size in 1Q26 was an extremely modest $15.3 million.

As a point of comparison, “hot money” institutional investors in this risk-off environment moved nearly $11 billion just in March alone from junk bond funds into investment grade bonds, a 24-fold increase from February according to JP Morgan.

In the current climate investment returns have been hard to come by. HFR, a leading hedge fund data provider, tallied industry performance in March to be -3.1%, the worst performance for hedge funds since March 2020 (admittedly, April 2026 may show some recovery in performance given the “TACO” phenomenon). For 1Q26, not surprisingly the best performing asset was the New York Mercantile Exchange (NYMEX) Heating Oil Index, which surged 96.3%; the top four performing assets were all oil related. Cocoa was in last place, generating a -45.6% return. Cambridge Associates recently released its most recent venture capital performance data (4Q25), which were 7.8% and 11.6% for early-stage and late-stage, respectively, which does not look too bad in comparison.

Investment activity in the healthcare technology sector continues to be both resilient and encouraging. According to Rock Health, $4.0 billion was invested in 110 companies in 1Q26, suggesting an annual pace of ~$16 billion in approximately 450 companies – or just 13% of the last OpenAI round. The average deal size of $36.7 million is nearly twice that of just two years ago. Although 1Q26 activity was slightly down from 4Q25 ($4.2 billion), it was up smartly from the $3.0 billion invested in 1Q25.

Digital Health Investment Activity

Source: Rock Health

An internal Flare Capital analysis of 1Q26 AI healthcare technology investments based on both Pitchbook and Rock Health data highlights an interesting market development. It certainly appears that early-stage round sizes are materially larger and being done at elevated valuations. Dilution in Seed and Series A rounds coalesced between 18 – 22% (which is obviously not how one should value a company but is an oft-cited benchmark nonetheless). In 1Q26, our data showed that for Seed rounds the average and median pre-money valuations were $20.7 million and $17.1 million, respectively. For Series A and B rounds average and median pre-money valuations spiked significantly to $96.4 million and $58.0 million, and $402.6 million and $459.8 million, respectively.

Arguably, the value creation curve historically has been more asymptotic for healthcare technology companies as it took a few years at the outset to establish product/market fit to confirm that the products or services lowered costs and/or increased revenues and/or improved outcomes. That dynamic seems to have changed as companies are raising more capital, sooner. The curve now appears more linear, up and to the right as product development timelines have compressed dramatically.

In 2023 healthcare became the fastest growing component in the personal consumption expenditure price index (PCE) and is now nearly 17% of the index. As of late 2025, healthcare accounted for more than 50% of the growth in PCE. Coupled with the growth in the healthcare labor force and aging U.S. population, healthcare costs continue to drive overall inflation. It is estimated that by 2030 there will be more Americans older than 65 than younger than 18 for the first time in the country’s history. Fortunately, Goldman Sachs analysts recently concluded that a 70-year-old today as the equivalent cognitive capacity of a 53-year-old in 2000.

All of this points to the extraordinary opportunity technology has to re-architect clinical and administrative workflows throughout healthcare, especially as AI can make the system less expensive, more effective. A recent study by Johns Hopkins estimates that 10% of Medicare Advantage enrollees will disenroll this year as insurers modify plan offerings due to costs, exacerbating issues of access. Already 14% of all ACA members have missed first premium payments in 1Q26. Notwithstanding that many healthcare providers are seeing improved operating margins through deployment of agentic AI technologies, anxiety is high over pending deep cuts to reimbursement rates, particularly for the Medicaid segment in 2027.

This is happening against the backdrop of the fiscal condition of the U.S. economy. Recent Congressional Budget Office estimates the federal deficit will be $1.9 trillion in 2026 or 5.8% of GDP, increasing to 6.7% in 2036. The trailing 50-year average was only 3.8%. The publicly held federal debt is projected to be 120% of GDP, up from 101% in 2026, eclipsing the all-time high of 106% in 1946. This deficit needs to be financed, which will run the risk of crowding out other investment opportunities and/or absorbing significant capital, likely to the detriment of other possible uses.

As Percent of U.S. GDP

Source: Congressional Budget Office

We hope you will join us for our next quarterly Expert Roundtable Series on June 9, 2026 at 12:00pm ET (register here). To stay connected, subscribe here for the latest updates, news, and insights from Flare Capital Partners.

2 Comments

Filed under Uncategorized

Healthcare’s Labor Paradox… 

That was certainly unexpected. The January payroll report was effectively twice as robust for jobs added to the U.S. economy than was forecasted just several days ago. This was powered by more than 82k and 42k new healthcare and social assistance jobs, respectively, accounting for virtually all of the 130k increase. This strength masks the overall weakness in employment across the other sectors of the economy. It also highlights one of the paradoxes of healthcare technology, which is how quickly automation and AI will lower administrative and clinical costs by reducing labor needs.

Change In Nonfarm Payrolls

Source: U.S. Department of Labor

It is estimated that there are 17 million (and as high as 22 million) healthcare workers in the U.S., according to the National Center for Health Workforce Analysis, accounting for more than 14% of all employees. Foreign born healthcare workers tend to be clustered at both the high- and low-ends of the skill and income distribution, with the lower skilled workers in the home health segment particularly vulnerable to the current Administration’s deportation program.

Foreign workers now account for approximately 15% of the U.S. population but are 39% of all home health aides, according to IPUMS, which tracks census data. In addition to the 230k deportees in 2025, there were another 270k people arrested at the border and another 40k people who “self-deported” in 2025, placing extraordinary pressure on all labor-intensive sectors of the economy.

Estimated Number of Deportees

Source: New York Times

The Centers for Medicare and Medicaid Services recently reported that the national healthcare spending reached $5.3 trillion in 2024, which is an increase of 7.2% over 2023 and is now comfortably above 18% of GDP. On a per capita basis, this is nearly $15,500. There were over 214 million enrollees in private health insurance in 2024, notably seven million more people due to the extension of enhanced Affordable Care Act tax credits. Without these credits, the average ACA enrollee will see monthly health insurance premiums spike from $888 to $1,904, according to KFF.

Against this backdrop there has been a profound shift in the economic composition of the U.S. population with the Middle Class being a smaller percent of the overall population as the affluent class has grown. Across all strata, household income increased significantly over the past half century, although the median income for the lowest income households increased only 55% as compared to 78% for the highest income household, according to the Pew Research Center. In 2022, the ratio of highest to lowest median income was 7.3x (it was 6.3x in 1970). While there may be proportionally fewer poor households, the ability to pay for healthcare has been severely impaired, putting significant strain on public resources and safety nets.

Distribution of U.S. Population

Source: American Enterprise Institute

The importance and magnitude of these social safety net programs is highlighted by an analysis by the American Enterprise Institute that concluded that a family of five with no earnings receives benefits totaling $55k annually. Furthermore, the powerful “leveling effect” of these programs is made more apparent when looking at a comparison of that same family earning $20k versus $80k annually. The higher income family effectively takes home only $11k more than the lower income family in after tax earnings given the substantial government subsidies. Interestingly, Goodwill Industries had its best year ever in 2025 with revenues in excess of $7 billion across its 3,400 stores.

These benefits may contribute to some of the hostility directed at these programs today. For example, Medicaid, which accounts for approximately 19% of all healthcare spending ($919 billion in 2024), is expected to decrease by over $900 billion over the next decade given announced cuts to the federal budget. In so doing, the number of uninsured Americans will increase by more than 7.5 million people.

Furthermore, more than 41.7 million people participated in the Supplemental Nutrition Assistance Program (SNAP) in 2024, according to USDA data. In aggregate, the SNAP outlays totaled $99.8 billion (~$187 per person) and while a federal program, the benefits are administered at the state level which has now introduced a chaotic patchwork system of guidelines and criteria. In certain states, these benefits have become much harder to access.

Hopefully, all these investments in public health are paying off. According to the National Center for Health Statistics, life expectancy in the U.S. hit a high-water mark in 2024 as the opioid crisis started to recede somewhat, dropping by 26%. Those born in 2024 could expect a life expectancy of 81.4 years and 76.5 years for women and men, respectively. The mortality rate in 2024 was 722.1 deaths per 100k.

While 1.2 million people died from cancer from 1990 to 2023 according to American Cancer Society data, the survival rates have improved notably with 70% of cancer patients living for at least five additional years after initial diagnosis. This underscores the criticality of continued robust investment in scientific discovery, and the lunacy of current officials’ attacks on research. Gavi, the Vaccine Alliance, estimated that 19.8 million lives were saved in the first year of the Covid vaccines being available.

In addition to scientific R&D investment, the pace of investment in new healthcare technologies improved in 2025 to $14.2 billion across, an increase of 35% over the $10.5 billion invested in 2024, according to Rock Health. The $4.2 billion invested just in 4Q25, the largest quarterly results for the past ten quarters, suggests a further strengthening of the sector into 2026.

While there were slightly fewer companies that raised capital in 2025 over the prior five years, the average deal size was significantly larger pointing to the impact of large AI financings. One word of caution: there are more than 600 companies which raised capital in 2021 – 2022 that have yet to raise another round. It is unclear what is to become of those companies as many undoubtedly are sub-scale.

Healthcare Technology Investment Activity

Source: Rock Health

There was a marked shift to AI-centric companies by investors in 2025, which now account for more than half of all healthcare technology financings. These companies are focused on solutions to automate many labor-intensive tasks in healthcare. Additionally, healthcare was 22% of all AI financings as compared to just 13% in 2024, pointing to an increased level of investor awareness and acceptance of the potential AI has in healthcare. This also likely reflects companies recasting themselves as AI-forward or AI-native now.

Source: Bessemer Venture Partners

The knock-on effect of AI euphoria has been profound on valuations and round sizes across all stages in the healthcare technology sector. One trend that is clearly evident is the significant “pull forward” of capital to the earliest rounds of financing. Seed investments in healthcare technology AI companies were on average $15.3 million in size at $41.6 million pre-money for an average post-money valuation of nearly $57 million. The pre-money valuation of the following Series A was only a 1.7x step-up, which compares unfavorably to the 3.4x step-up from the Series A to Series B rounds. Even more surprising was the absence of a step-up from the Series B to Series C rounds, perhaps suggesting that many Series B companies struggled to show meaningful commercial progress. 

Healthcare Technology AI Investment Activity (through 1H25)

Source: Proprietary Flare Capital analysis based on Rock Health and Pitchbook databases

The promise of healthcare AI is to materially lessen the reliance on labor in clinical and administrative workflows. In spite of essentially flat Medicare rate increases announced for 2027, there are several promising federal initiatives to facilitate greater efficiencies such as the ACCESS Model (AI-supported care models for chronic disease) or the WISeR Model (AI-enhanced prior authorization) or the MAHA ELEVATE Model (evidence-based functional lifestyle medicine interventions). Quite clearly, the current Administration is pushing to remove many of the AI guardrails in place to encourage business model transformation.

One interesting development has been the extraordinary level of chatbot engagement for health-related matters. OpenAI recently rolled out a health tab in ChatGPT that now has 40 million daily visitors. Patients are uploading medical records and test results, desperately looking for guidance and insights while circumventing already capacity constrained providers. This phenomenon underscores the opacity and frustration of engaging with the healthcare system today that operates like a gated community as patients scurry into corners of the internet looking for answers. It also highlights the need for greater “data liquidity” so that fringe commentators do not receive media attention in the absence of authoritative clinical voices.

Interestingly, it is not just patients looking for online assistance. Physicians are now readily embracing AI tools at the point-of-care. Given the pressure on healthcare labor, such advances, if reliable, will provide significant leverage for the provider workforce.

Most Popular AI Tools for Physicians

Source: 2025 Physicians AI Report

Notwithstanding the precipitous drop in consumer confidence this past month from 94.2 to 84.5, the lowest monthly reading in a dozen years and lower than at the depths of the Covid pandemic, public market investors seem to be returning to the healthcare sector. Ironically, general consumer sentiment appears to have soured on the state of the jobs market, although jobs remain relatively plentiful in the healthcare sector even with rapid AI adoption. According to national net buy/sell trading data, an analysis by Morgan Stanley concluded that of the eleven tracked sectors, healthcare experienced the greatest month-over-month improvement in overall investor sentiment to start the year.

Monthly Sector Rotation

Source: E*Trade, Morgan Stanley

We hope you will join us for our next quarterly Expert Roundtable Series on March 3, 2026 at 12:00pm ET (register here). To stay connected, subscribe here for the latest updates, news, and insights from Flare Capital Partners.

Leave a comment

Filed under Uncategorized

Venture Capital: All Chips on Black vs. Playing the Percentages…

Over the past 100 years there have been 29,078 publicly listed U.S. stocks, of which 4% of them accounted for nearly all the economic wealth created this past century. Less than 100 companies were responsible for half of those gains. Approximately 52% of those companies had negative cumulative returns according to research from Arizona State University.

Those same researchers then studied the 63,785 global stocks between 1990 and 2020 and showed that 55% of U.S. and 57% of non-U.S. stocks generated returns below that of a one-month Treasury bill. In that same period just five companies accounted for a shade over 10% of the $75.7 trillion of the net equity value created. Half of that wealth creation was by 0.25% of the companies; all of it by just 2.4% of the companies during that period.

Issues swirling around the concentration of capital, of wealth, of resources are quite acute now. According to Bloomberg, the top ten U.S. technology founders saw their collective net worth increase by $550 billion to $2.5 trillion in 2025, largely on the coattails of the AI phenomenon. The top ten private companies are now worth $2 trillion.

Globally, hedge funds had their best year in 2025, increasing assets by $628 billion to over $5 trillion, in spite of only generating a 12.8% return. This was rather middling when compared to dozens of other asset classes (NASDAQ was up 20.4%, S&P 500 up 16.4%). Silver was the top performing asset this past year, increasing over 142%; three of the top four assets happen to be metals. Sadly, the poorest investment in 2025 was orange juice, which dropped nearly 59%.

The venture capital industry is navigating the noisy distractions coming from D.C., while coming to terms with the impact of AI during a confusing but reasonably good economic climate. In December inflation was 2.7% and the unemployment rate ticked down to 4.4%. Additionally, labor productivity increased 4.9% in 3Q25 while output jumped 5.4% with hours worked increasing by just only 0.5%. As a point of comparison, annual improvements in labor productivity in the 2010s averaged 1.1%.

Not surprisingly, most of the recent venture capital activity was centered on AI as each sector of the economy scrambles for solutions to drive additional productivity gains. Of the $339.4 billion invested in 16,709 companies in 2025, $222.1 billion was attributed to 5,793 AI companies according to Pitchbook (65% of the capital, 35% of the companies).

Globally, $469 billion was invested according to CB Insights, 48% of which was in AI companies, and goes on to caution that many of the marque venture funds have become highly “concentrated AI funds, not diversified portfolios.” Obviously, AI round sizes were larger than for non-AI companies: $38.3 million versus $10.8 million, respectively, underscoring profound investor exuberance.

S&P 500 Companies’ Real Revenue per Worker

Source: Bank of America US Equity & Quant Strategy, FactSet, Bloomberg

The investment activity over the course of the year saw a notable increase in 4Q25, returning back to the quarterly pace of euphoric 2021. Notwithstanding that the total number of investments continued to modestly decline, the average deal size spiked to $27.1 million, likely reflecting several mega-AI financings. In fact, eight of the eleven rounds greater than $1 billion this past quarter were for AI companies; those eleven companies raised $37.4 billion or 41% of 4Q25’s totals. Anthropic’s $15 billion “venture” investment punctuated this past quarter’s activity.

Venture Capital Investment by Quarter

Source: Pitchbook

Underneath a relatively serene surface are profound challenges to the venture capital model. First and foremost is the significant lack of liquidity. Arguably, liquidity serves as a proxy for the relevance of much of what VCs do: does the inability to sell portfolio companies point to a general apathy or indifference towards those companies? Obviously, some founders may choose to simply stay independent, or the board may determine that the runway for significant additional value-creation is long so best to stay the course. More often than not, though, that is not the case.

An analysis by Pitchbook highlights the extreme state of affairs. Since 2022 net cash flows from limited partners totaled $197 billion through 2Q25. While this does not yet reflect the significant exit activity in 2H25, the venture capital model is predicated on the ability to recycle capital. This does not mean to imply significant impairment but rather it underscores the challenges over the past few years to find attractive buyers coupled with a largely non-existent IPO market. Having said that, though, there are some concerns that companies funded several years ago may be at severe risk of obsolescence given the rapid pace of change.

Net Cash Flow to Limited Partners ($B)

Source: Pitchbook (as of 2Q25)

Notwithstanding the lack of predictable and material distributions back to limited partners, exit activity in 2025 started to recover with $297.6 billion across an estimated 1,635 transactions (average size of $182 million). The year ended with an upswing with 4Q25 exits totaling $93.6 billion across 422 transactions (average size of $222 million) and was the strongest quarter for exits since 4Q21 ($221 billion, 565 transactions, average size of $391 million). IPO activity in 2025 continued to be somewhat underwhelming with only 48 IPOs of venture-backed companies, although the total value was $116.7 billion, both ahead of 2024 amounts of 44 companies and $41.4 billion, respectively.

Another industry concern is that fewer firms are raising much larger funds, exacerbating a “bar belling” of the industry. Fundraising in 2025 continued the anemic downward trend started in 2022 with only $66.1 billion raised by 537 funds (average fund size of $123 million; median fund size was only $26 million). More than $23 billion of the total raised in 2025 (35%) was by funds greater than $1 billion in size. Furthermore, only $6.6 billion was raised by 92 first-time fund managers (average fund size of $72 million), reflecting further concentration among larger established branded firms.

With just under $300 billion of “dry powder,” the venture capital industry certainly has the wherewithal to power through economic turmoil. But even this investment capacity underscores the concentration of capital among fewer investment managers. Nearly 60% of the “dry powder” is held by funds greater than $500 million, and yet those funds represent just under 7% of the number of funds raised over the past four years. Similarly, only ten private equity funds raised 46% of all capital in 2025 according to the Financial Times. A knock-on implication of this concentration might well be fewer start-ups being funded as larger funds tend to make larger, later stage investments.

Venture Capital “Dry Powder” By Fund Size

Source: Pitchbook (as of 1Q25)

The venture capital industry has been referred to as a game of grand slams – wish it were that straightforward. According to MLB.com, in the 2025 season there were 120 grand slams sprinkled across 163,685 at bats (0.07% of each at bat). While the average is markedly more attractive in venture capital, failure is unfortunately a reality. Data from S&P Global Market Intelligence shows that bankruptcies in 2025 were at a 15-year high with 785 filings. A review of failure rates by stage reveals two interesting observations: failure rates decrease as companies scale and the top decile of companies ranked by valuation at each round fail less often.

Failure Rates by Stage

Source: Pitchbook

While these data might suggest a reasonably predictable progression up and to the right, occasionally interim financings are more “complicated.” If milestones are not hit, but existing investors remain engaged and enthusiastic, it is not uncommon for the subsequent round to be at a lower valuation and/or with economic terms to attract (i.e., induce) additional capital. This is a dynamic that is closely watched to gauge the health of the venture ecosystem. Fortunately, the percentage of down and flat rounds has improved in 2025 with less than 20% as compared to mid-20% in 2023, but not as good as the rocking 2021 – 2022 timeframe when that was in the mid-teens.

Percentage of Down and Flat Rounds

Source: Pitchbook

It is estimated that today there is $261 trillion of investable assets globally. In fact, since the 1990s as a percentage of global GDP, assets have increased from 75% to approximately 200% (~120% equities, ~80% bonds/other). According to the National Venture Capital Association, at the end of 2024 there were 3,111 firms managing $1.25 trillion of venture assets in the U.S., a relatively modest portion of the global market. Recently released data  from Cambridge Associates, a leading institutional advisory firm, presented venture capital returns data as of June 2025 that highlight the recent “air pocket” these firms are navigating. As of 2Q25, the one-, three-, five-, ten-, and 15-year returns were 11.4%, 0.1%, 15.0%, 13.1%, and 15.1%, respectively.  

Limited partners need to stay convinced that commitments to venture capital funds will drive enhanced returns while also diversifying overall portfolios. The conundrum now is whether the incremental volatility is justified in light of significantly reduced liquidity. A comparison of various asset class 15-year returns by Pitchbook highlights the dilemma confronting investors today.

Returns by Asset Class

Source: Pitchbook (as of December 2024)  

Fortunately for investors seeking direct exposure to the AI craze, venture capital remains the most direct, efficient way to do that, as it has for every other transformative wave of innovation. As these new AI capabilities demonstrate attributed enduring economic value creation expect to see marked increase in liquidity (arguably there are early signals in 4Q25 data). In addition to the improved productivity metrics, another indicator that technology may be profoundly replacing labor is evident in the share of economic output that is captured by workers’ wages, which has never been as low as it is now. What was once in the mid-60% range has dropped now to below 54%, suggesting we have become meaningfully less reliant on humans.

That may be the more troubling development…

Share of U.S. GDP for Labor

Source: Bloomberg

We hope you will join us for our next quarterly Expert Roundtable Series on March 3, 2026 at 12:00pm ET (register here). To stay connected, subscribe here for the latest updates, news, and insights from Flare Capital Partners.

3 Comments

Filed under Uncategorized

Secondary Market: Second Time’s a Charm…

Global alternative assets under management was estimated to be $19.5 trillion at the end of 2024 according to JP Morgan Asset Management, of which approximately $4 trillion is in private equity, and half of that is in funds older than four years. It is somewhat surprising that only in the past couple of years has there been an explosion in secondary market activity. And yet, even as it looks that 2025 will be a high-water mark in secondary volume according to Lexington Partners, a leading secondaries investment firm, the $200 billion of transactions will only be about 1% of global AUM.

Over the past dozen years the level of activity has increased ~8x. In the history of secondary market transactions, 80% of the activity has been just in the past decade. Up until about five years ago, the amount of secondary “dry powder” covered at least one to two years’ worth of transaction volume. That changed in 2025 with the rapid maturity of the secondary market and the acute structural need for greater private investor liquidity in the face of a dramatic drop in M&A and IPO volume over the past few years.

Secondary Transaction Volume and Amount of “Dry Powder” Available in Years

Source: Lexington Partners

Secondary transactions generally come in two flavors: (i) limited partners selling their interests in funds (“LP-Led”); and/or (ii) general partners creating “continuation vehicles (CV)” to sell specific portfolio companies to a new entity, affording original investors liquidity or the opportunity to roll-over into the CV (often referred to as “GP-Led” transactions). According to Jefferies, there was $103 billion of secondary market volume in 1H25, of which $56 billion was LP-Led and $47 billion was GP-Led. This level of activity was 51% greater than the $68 billion in 1H24.

Institutional investor interest in the secondary market is highlighted by the dramatic increase in AUM for the sector. According to Pitchbook, the total capital was $687 billion in 1Q25, a nearly 20x increase over the past two decades. It is estimated that approximately 10% of inflows to secondary funds are now from retail investors, further underscoring the broader acceptance. Secondary funds are often the only approach to get investment exposure to massively successful private companies like SpaceX and OpenAI. Notably, Goldman Sachs, Morgan Stanley, and Charles Schwab all acquired secondary investment firms in 2025.

Size of Secondary Market (AUM in $B, through 1Q25)

Source: Pitchbook

Through 3Q25 secondary funds have raised $105 billion, putting 2025 on pace to be the strongest fundraising year. There has been $122.6 billion raised over the trailing four quarters, which is an increase of 22% over the prior period according to Pitchbook. Jefferies estimated that at the end of 2Q25 that there was $302 billion if dedicated available secondary capital. As a point of comparison, the private credit industry increased 100-fold since 2006 to almost $700 billion.

Secondary Fundraising (through 3Q25)

Source: Pitchbook

Lexington Partners estimates that 12.7% of all commitments to global private investment funds between 2005 – 2017 have been sold in the secondary market. Just since 2018, over $5.8 trillion has been committed to private investment funds, suggesting significant runway for future LP-Led transactions.

For LP-Led transactions, the discount to reported Net Asset Value (NAV) is a critical marker that investors track. Across all asset classes, pricing was 90% of NAV for 1H25 which was slightly down from 91% in 2024 but sharply greater than 81% in 2022. Buyout funds tend to trade with the smallest discount to NAV while real asset and venture capital funds trade at significantly larger discounts, in part due to the perceived mortgage refinancing risks for real estate and that much of the limited partner commitments for venture capital funds are likely still unfunded and those portfolio companies will require additional capital. In general, U.S. and European funds traded at smaller discounts while Asian and Emerging Market funds often trade at 30+% discounts to NAV.

LP-Led Portfolio Pricing

Source: Jefferies

Limited partners are embracing secondary transactions as an approach to create liquidity and have started to sell stakes in higher quality funds, not just those perceived as “bad” or underperforming funds. Historically, limited partners would sell older, poorly performing funds but in 1H25 the weighted average vintage of all funds sold was seven years old, according to Jefferies data, with younger funds trading at a smaller discount. In 1H25 53% of all transaction volume was for buyout and private equity funds, while venture capital and growth equity accounted for 22% of the total.  

More liquidity bolsters fundraising activity. It is estimated that there is $3.7 trillion of value tied up in nearly 830 “unicorn” companies. Coupled with the lack of significant M&A and IPO volume, investors are stuck with the conundrum of how best to turn unrealized gains into realized gains. This has been made even more urgent if one anticipates a dramatic correction for frothy AI-hyped portfolio companies. Pitchbook tallied over 13,000 M&A deals in 3Q25 worth $1.3 trillion so there may be a glimmer on the horizon.

The explosion in the availability of private credit affords private equity funds the possibility for dividend recaps, whereby free cash flow positive portfolio companies may be able to access debt for distributions, but that is not an alternative for most venture-backed portfolio companies. 

U.S. Venture Capital Exit Activities (LTM)

Source: Pitchbook

Over the latest twelve months the volume of M&A activity ($107 billion) rivalled that of total IPO activity and was within shouting distance of secondary transaction volume for venture capital funds. The experience for private equity funds is comparable. This manufactured liquidity underscores the severe need for distributions. Historically, private equity funds tended to have an exit-implied distribution yield that ranged from high-teens to low-30s percent; that is, how much of the NAV is distributed in a given year. According to recent Pitchbook data, there is estimated to be a nearly 400 basis point delta (16.0% vs 11.8%) between what announced M&A activity would suggest and the actual distribution yield of 16.0%. This gap accounts for the marked increase in GP-Led transactions.

Distribution Yield for Private Equity Funds

Source: Pitchbook

There is no longer shame attached to GP-Led transactions as they often involve some of the best performing portfolio companies that fund managers are reluctant to let go of. There was a 68% increase in these transactions in 1H25 over 1H24 with more than $47 billion in volume (87% are continuation vehicles, 13% are structured equity, fund finance, tender offers). More than 90% of GP-Led transactions in 1H25 were priced at less than a 10% discount to NAV. Approximately 60%, 17%, and 8% involved buyout, private credit, and venture capital funds, respectively. There was a marked increase in secondary transactions involving real estate funds given the dramatic inflows in digital infrastructure assets (i.e., data centers).  

GP-Led transactions are not for everyone. According to data from Hiive, the top 20 traded private companies in the secondary market over the last 12 months account for 96% of all deal value; the top five account for 74%. Data from Sydecar suggests that the number of secondary special purpose vehicles that are raised to invest in these sought after private companies increased over 680% and the amount of capital grew by 1,340% over just the past two years.

A recent survey of 68 secondary investment firms by Lazard points to a possible rotation away from the most popular names to middle-market opportunities (60% stated that 60+% of their transactions will be middle-market focused) as these transactions become more routine.

During a week when regulators announced the roll back of corporate lending rules instituted in 2013 by the Federal Deposit Insurance Corporation and the Federal Reserve to limit the amount of riskier loans, UBS announced that there are now 2,900 billionaires who control $15.8 trillion of cumulative wealth, much of which is in private investment vehicles. Undoubtedly some of this wealth is in crypto assets, which has suffered through a miserable few months with Bitcoin dropping 35% just in the past several weeks. Hopefully a portion of the $3.7 billion of November Bitcoin ETF outflows make its way to secondary funds.

Bitcoin ETF Fund Flows

Source: SoSoValue

2 Comments

Filed under Uncategorized

This Should Work…

Investments in healthcare technology should work. There can be a legitimate debate about the wisdom of the magnitude of overall AI investment activity, now estimated to be $320 billion just in 2025, but undoubtedly most will see significant healthcare benefits from this infrastructure buildout.  But there may also be merit to the argument that certain knock-on effects of AI will undermine for some improvements in the quality of life. At a minimum, it is not entirely clear that the agentic arms race unfolding between payors and providers will entirely help patients versus improving the economics of the combatants.

Not surprisingly, the geographic diversity of the U.S. between urban / suburban / rural directly influences one’s life expectancy. The Economic Innovation Group has developed a Distressed Communities Index which is a composite of factors including poverty levels, education, housing, median income, and employment status. Just over half of Americans live in suburban zip codes, and nearly two-thirds of suburbanites reside in what are deemed Prosperous and Comfortable areas. Those fortunate residents have life expectancies nearly eight years longer than those living in Distressed areas. Just over 15% of Americans live in Distressed zip codes.

Life Expectancy by Distress Score

Source: Economic Innovation Group

Bank of America estimates that those earning more than $250k represent approximately 10% of all Americans and now account for over 49% of all spending, a significant step-up from 35% just 30 years ago. This will be enormously useful for those more fortunate given healthcare cost inflation has spiked according to recent Consumer Price Inflation data. Annual hospital costs and prescription drug costs are expected to increase 6.8% and 7.0% in 2025, respectively, according to Peterson-KFF forecasts. KFF goes on to project that the cost of an annual family health insurance plan is now nearly $27k, up 6% from 2024 levels.

Next year is likely to be even worse. Large employers are expecting overall health costs to increase 9% in 2026, in large measure due to a 12% jump in drug spending (oncology, GLP-1 being principal contributors). A survey from the Business Group on Health expects employers to meaningfully cut costs (versus passing increases on to employees), perhaps under the aircover of expected AI efficiencies.

Therefore, many Americans are now highly reliant on an array of important social services with nearly 24% on Medicaid or the Children’s Health Insurance Program (CHIP) – that is 85 million people. It is estimated that up to 16 million will lose health insurance coverage by 2034 due to the One Big Beautiful Bill Act. Should the government shutdown continue into November, an estimated 42 million low-income people will not receive food stamp benefits from the Supplemental Nutrition Assistance Program. As many of these programs are now under siege, the expectation (i.e., hope) is that investments in healthcare technology and AI will be able to improve care services for those most disenfranchised, living in Distressed communities to extend or augment the existing healthcare infrastructure.

Percentage of Country Receiving Social Benefits

Source: Census Bureau, USA Facts (2022)

Notwithstanding the significant costs incurred to provide care to Americans, estimated to be over $12k per capita, life expectancies are middling and on parity with many developing countries. This is not something to be particularly proud of in light of how much is spent on healthcare and technology – and points to the profound opportunities to re-architect the healthcare system.

Per Capita Healthcare Expenditures vs. Life Expectancy

Source: Silicon Valley Bank

Perversely, the dramatic investment in AI infrastructure may have significant negative health implications for some due to increased social isolation and loss of many jobs. A recent Financial Times analysis concluded that specifically young men and the unemployed exhibited a significant – and recent – spike in “deaths of despair.”

Percentage of Men Reported Feeling Isolated

Source: Financial Times, BBC Loneliness Experiment

Those who reported being isolated were nearly 3x as likely to die from substance abuse or suicide. The heightened incidences of online porn and gambling addiction have been widely reported. The prospect of widespread job loss due to AI will be devastating to those who are unable to adjust, especially in light of compromised social safety nets. The CEO of Heineken recently argued that his alcoholic products have health benefits given they are “social lubricants” which help people feel less isolated. This has been reflected in the company’s marketing campaigns for generations.

In spite of some of these concerns, the healthcare sector largely has embraced AI and identified bespoke solutions to transform administrative and clinical workflows. Today there is an agentic arms race between providers and payors pointing AI agents at one another to optimize reimbursement payments. A survey by Menlo Ventures concluded that 22% of all healthcare organizations have secured commercial AI licenses (versus 9% overall). Importantly, though, 27% of providers have as opposed to only 14% of payors, highlighting the current imbalance in automation capabilities.

An analysis by Bain highlights the continued priorities around revenue cycle management (e.g., documentation, coding, billing) and clinical workflow optimization, code for improving cash flow and reducing operating costs. Investments that do not directly have immediate ROI (~3-5x in first year) tend to fall lower down the stack of needs. Notably, the urgent requirements at the start of the pandemic to have providers become fully on-demand, always on, and virtual (e.g., telehealth and patient engagement) are meaningfully less critical now.

Survey of Current Provider Budget Priorities

Source: Bain

A similar Bain survey of payors shows a distributed set of priorities focused on product design (network and plan design) and member coordination. Many of the other priorities impact issues involving payment and cash flow and lend themselves nicely to being automated. In the face of increased medical loss ratios, a spike in utilization rates, lower reimbursement, and rapidly shifting member eligibility payors are aggressively considering AI solutions. Better determining provider quality will improve network design such that members will access more appropriate (i.e., likely less expensive) care at the right time and setting, improving member experience and reducing churn. Ironically, member-facing activities tend to be the first use cases to be automated (e.g., call center, member engagement, benefits verification).

Survey of Current Payor Budget Priorities

Source: Bain

After a challenging period post pandemic, this year many of the healthcare public stocks have performed reasonably well and for some sectors such as hospitals and large service providers, they have significantly outperformed year-to-date some of the broader market indices. Of note, the Medicaid sector has struggled as have smaller providers (sub-scale), risk-bearing entities, and tech-enabled virtual care companies, according to an analysis by J.P. Morgan.

Sector Stock Performance (2025 YTD)

Source: J.P. Morgan, Bloomberg

At the end of 3Q25 the Healthcare Technology Public Company Index (46 companies) tracked by MTS Health Partners was trading at an average of 3.0x and 2.8x 2025 and 2026 revenues, respectively, and 17.0x and 15.2x 2025 and 2026 EBITDA, respectively. The Index was forecasting an average 7.1% revenue growth for 2026, a marked slowdown from the 9.3% increase over last year, reflecting many of the industry headwinds. The most highly valued sub-sector was the Pharma-Tech cohort, which is valued at 5.1x and 16.6x 2026 revenues and EBITDA, respectively. Value-Based & Tech-Enabled Primary Care and Tech-Enabled Payers were the two lowest valued sub-sectors at the end of the quarter, likely reflecting the capital intensity of risk-bearing business models.

Investor excitement in healthcare AI is reflected in digital health investment activity, notwithstanding challenges to reconcile the more modest valuation multiples for publicly traded companies with those of lofty private market multiples. According to Rock Health, year-to-date $9.9 billion has been invested in 351 companies. For 3Q25, $3.5 billion was invested in 107 companies putting the sector on pace to have ~$14 billion invested in around 450 companies, which would signify an encouraging recovery closer to 2022 levels.

There continues to be evidence of further capital concentration around emerging winners in the digital health sector. Average investment size increased significantly year-to-date to $28.1 million from $20.4 million last year, driven by the dramatic increase in round size for AI companies. The top three focus areas in 2025 are (i) clinical workflow (ii) non-clinical workflow and (iii) care coordination, according to Rock Health. Silicon Valley Bank estimated that 38% of healthcare technology investments this year were in “mega rounds” of over $100 million, up from 28% in 2024.

Digital Health Investment Activity

Source: Rock Health

Expect further consolidation among the great unwashed masses of sub-scale private healthcare technology start-ups, which will ultimately be healthy for the sector. Going forward fewer companies will likely be started against a backdrop of more capital being invested in the sector. In addition to the resilience in the pharma-tech sub-sector, there is increasing investor chatter around several emerging themes such as the development of proprietary healthcare data sets (versus building on top of general purpose LLMs) and “hardware delivered AI.”  Never a dull moment…

Leave a comment

Filed under Uncategorized

This Better Work…

The private credit market shuddered this past week with the disclosure of significant portfolio issues tied to the fraud and bankruptcies at First Brands and Tricolor Auto Group. Fears of further credit concerns saw 74 regional banks lose over $100 billion in market value as chatter of a possible contagion emerged, according to an analysis by Bloomberg.

Given the magnitude of capital required for the announced AI infrastructure buildout, as much as $320 billion in 2025, robust and accessible capital markets will be essential. J.P. Morgan now estimates that there is $1.2 trillion of debt linked to AI issuers, accounting for 14% of the high-grade debt market, making AI the largest sector.

Against the backdrop of the government shutdown, the state of the labor force has several flashing warning signs that provide some cautious insights into where the U.S. economy might be heading. For the first time since the outset of the pandemic, the number of unemployed workers is now greater than the number of open positions (“V/U ratio”). Over the past 25 years, a decline in this ratio has been correlated to a recession.

Number of Unemployed Workers

Source: Bank of America, Haver Analytics

Additionally, declines in temporary service jobs often indicate the onset of a recession. With approximately 2.5 million temporary service workers, these tend to be the first people let go. There are now hints of a significant correction looming as the level of temporary employment has been dropping for over a year, according to an analysis by Charles Schwab. The absence of government labor data further heightens investor anxiety.

Changes in Temporary Services Labor Force

Source: Charles Schwab

With the government shut down, which Bank of America estimates is costing the U.S. economy $15 billion per week, investors have focused greater scrutiny on other economic indicators. Goldman Sachs has developed its index of Current Economic Activity which is a composite of several foundational pillars of the U.S. economy. Notably, this index has declined over the past several months, with particular weakness in the Manufacturing sector. “Liberation Day” this past April was a particularly bad month, which further underscores lingering investor concerns about the haphazard application of the U.S. tariff strategy.

Indicator of Current Economic Activity

Source: Goldman Sachs Research

But valuations of financial assets and commodities have been on a tear. The best performing asset in 3Q25 was Silver, which increased over 29%, followed by Coffee, up a hyper-caffeinated 22.2%. Surprisingly, Cocoa declined 27.9% which industry analysts attributed in large measure to a decline in chocolate consumption (GLP-1 impact?). The NASDAQ Index increased by 11.2% while the S&P 500 Index increased by a more pedestrian 7.8% in the quarter. Globally, equity values are now approximately 120% of worldwide GDP, which is converging on an all-time high.

Global Stock Market Capitalization as Percent of Global GDP

Source: Goldman Sachs

Obviously, the artificial intelligence phenomenon is driving profound investor interest in all-things AI. But that excitement is not just contained to AI. Speculation euphoria is driving other sectors as well, perhaps fueled by the enabling capabilities of AI. The crypto sector is now valued at over $4 trillion. Gold has increased 59% just this year alone. According to the American Gaming Association (“AGA”), there was $150 billion bet on spots in 2024, with the AGA indicating that it will be “significantly higher” in 2025.

Business Insider recently estimated that $320 billion will be spent on AI infrastructure this year, which is an outsized contributor to overall domestic GDP growth. Bridgewater calculated that 35% – 45% of GDP growth year-to-date is just due to the technology sector’s investment in AI infrastructure. Absent this investment, GDP growth would likely be running at less than 1.0% in 2025.

Contribution to U.S. GDP Growth

Source: Bridgewater

A Harvard study paints an even more sober or daunting picture, concluding that through the first six months of 2025, 92% of GDP growth was attributed to AI data center development, highlighting the economy’s reliance, and therefor exposure, to the technology infrastructure build-out today.

Another word of caution: much of this infrastructure may have a relatively short shelf life. ChatGPT is less than three years old and now NVIDIA is releasing its next generation of AI chips (Blackwell Ultra and Vera Rubin platforms) which effectively obsoletes chips from several years ago. Chip depreciation is estimated to be as much as half the cost of running data centers (power is only between 2% – 6%), so the path to value capture may be elusive for some participants.

This investment – so far – appears to be justified. Nearly 18 months ago Google reported that 9.7 trillion tokens (a unit of data processed) per month were processed across its products. This past May that number spiked to 480 trillion, an increase of 50x in just twelve months. This increased to 980 trillion just three months later and is now running at 1.3 quadrillion tokens per month.

An analysis from McKinsey & Co from earlier this year offers an often-cited word of caution though. Notwithstanding that U.S. companies are estimated to spend $62 billion on AI solutions this year, 80% of surveyed companies reported “no significant bottom-line impact” with 42% of respondents terminating their AI initiatives.

The rapidly emerging dilemma is now how best to finance all these AI infrastructure investments. Setting aside the scrutiny on “circular deals” with the leading companies investing in each other to purchase one another’s’ products, which has opened a non-trivial systemic risk debate, investors have piled into various technology sector funds (below) and AI entrepreneurs have been embraced by venture capitalists.

Technology Sector Fund Flows

Source: Bank of America Global Economics

This rising AI tide is most definitely lifting all venture capital boats. According to Pitchbook, there was $80.9 billion invested in 3,175 companies in 3Q25. Year-to-date 64% of all venture capital investments were in AI companies, yet this represented less than 38% of all companies, reflecting the extraordinary round sizes of AI financings. There were nine $1.0+ billion AI rounds in 3Q25 alone. Across every stage the median deal size increased year-to-date over 2024 by more than 10%. Pre-seed, Seed, Series A, Series B, Series C, Series D+ median round sizes year-to-date are $0.5 million, $3.8 million, $14.0 million, $32.4 million, $56.5 million, and $100.0 million, respectively.

Quarterly Venture Capital Investment Activity

Source: Pitchbook

Even more dramatically was the increase in median pre-money valuations year-to-date over 2024 levels. For instance, Series C valuations increased from $225.0 million to $307.0 million, and Series D+ spiked from $630.9 million to $838.8 million. Notably, the average Series D+ valuations skyrocketed from $1.8 billion in 2024 to just over $4.0 billion year-to-date, reflecting a handful of extraordinarily large AI infrastructure investments.

This has led to a crowded pasture of unicorns. According to CB Insights, there are now 498 AI unicorns that are valued collectively at $2.7 trillion, 100 of which were founded just since 2023. It is estimated that there are more than 1,300 AI start-ups valued at more than $100 million each. Across all sectors, Pitchbook estimates that there are 828 unicorns with an average post-money valuation of over $3.7 billion. Year-to-date more than $142 billion was invested in 284 unicorns, representing 57% of capital invested but only 2.7% of companies.

Unicorns Created by Quarter

Source: Pitchbook

The question confronting most venture capital investors turns on when the industry will see predictable liquidity (i.e., exits). There are glimmers of hope here. Already year-to-date exit activity is running more than 33% greater than all of 2024 with $204.9 billion across an estimated 1,135 exit transactions. While the average exit value is of modest utility, it is considerably greater year-to-date at more than $180 million when compared to $121 million for all of 2024. Given the concentration of invested capital in a relatively select few companies, one might also expect that a relatively small number of companies will generate the bulk of the investment returns.

To be more specific, a recent analysis by the Financial Times found that just ten unprofitable AI companies saw an increase of over $1 trillion in aggregate valuation over the past twelve months. Those companies include Anthropic, Anysphere, Databricks, Figure AI, OpenAI, Perplexity, Scale AI, Safe Superintelligence, Thinking Machines Lab, and xAI.

Exits drives fundraising. To refill venture capital coffers, limited partners need to see robust distributions. Year-to-date 376 funds were raised that totaled $45.7 billion (average fund size of $122 million), which candidly is quite anemic when compared to 2024 (832 funds and $85.7 billion raised), although 3Q25 was stronger than 1H25 with $19.1 billion raised over 138 funds (average fund size of $138 million). Of the 376 funds raised this year, only 68 were from new firms (average fund size of $71 million), underscoring the challenges to break into the venture capital industry.

The profile of great venture capital funds tends to have returns generated by a small number of portfolio companies, which is mirrored in the overall venture capital industry with 3,111 firms managing 7,969 funds; that is, top decile fund performance is significantly better than the average fund. Carta, a leading private markets analytics firm, recently published an analysis of 1Q25 venture capital fund performance which highlighted this performance distribution by vintage. Notably, the relatively poor performance of the 2021 vintage reflects the dramatic inflow of venture capital that year. This also underscores growing concern about “capital absorption” when too much is invested, too quickly.

Venture Capital Performance by Vintage Year  

Source: Carta

American “exceptionalism” has been bandied about for generations but has been recently called into question. Over the past 15 years, the S&P 500 Index has performed significantly better than the basket of all other countries, and yet approximately 80% of the performance can be attributed to a strong U.S. dollar and valuation multiple expansion. Business fundamentals are a relatively small contributor to the overall performance, and in fact, analysts at GMO conclude that over the past five years the difference in performance between the U.S. and the rest of the world nearly vanishes.  Notably, the bulk of superior performance is reflected in a small number of companies and was generated prior to 2015.

Performance of S&P 500 vs. MSCI World Index (ex-U.S.)

Source: GMO, Compustat, S&P Global, MSCI

 

Undoubtedly, these new AI capabilities are profoundly exciting and will be unexpectedly disruptive. The question will quickly focus on whether attractive returns can be generated by these investments. Investors will be listening carefully to reports from Corporate America over the next several quarters, given how much capital will be tied up in this infrastructure. We better hope it all works…

And please join us for our next quarterly Expert Roundtable Series webinar on December 9, 2025, at noon ET. And subscribe here to follow other news and insights from Flare Capital Partners.

8 Comments

Filed under Uncategorized

Another Great Add to the Flare Capital Team…

We could not be more excited to announce that Alyssa Tsenter has joined the firm as a Senior Associate. Venture capital firms add to their investment teams infrequently, so each hire is important and deliberate with an extended interview process to assess capabilities, commitment, and all-around compatibility. While we will make a few hundred investment decisions together over the course of a fund, we might only make a handful of hiring decisions. Notwithstanding that, this one was easy as we continue to build our core investment team.

Alyssa earned her MBA from Harvard Business School this past spring, where she focused her course work on the healthcare industry. Prior to HBS, she spent nearly five years at ZS, a leading life sciences management consulting and technology firm. While there she worked on projects that would shorten R&D development timelines, elevate promising pharma assets, and rearchitect innovation processes. Her understanding and fluency of the life sciences sector underscores our increased focus on partnering with entrepreneurs to increase operating efficiencies across the entirety of the life sciences landscape. Alyssa also received an undergraduate degree in Chemistry with an emphasis in Chemical Biology from the University of Southern California.

After our first meeting with Alyssa, her passion and deep understanding of this sector’s many complexities and nuances were abundantly clear. Additionally, while in business school, Alyssa interned for a few venture capital firms and venture studios which sparked her interest in investing in technologies that will transform the healthcare and life sciences industry.  

And what an endorsement to get an unsolicited note from a senior HBS faculty member when he learned of Alyssa’s joining the firm – “she was an absolutely terrific student…” Further confirmation of what we all thought.

Alyssa also has an adventurous side. Her parents emigrated as teenagers from the Soviet Union, which left an indelible impression on her. She graduated early from USC to travel the world teaching yoga in places like Thailand, Israel, Peru, and Panama.

Please welcome her to the Flare Capital team…

A quick update on our Flare Scholars program and our pre-seed investment activities with Flare Scholar Ventures (FSV). Since inception, we now have 446 current or former Flare Scholars, who are passionate young professionals from many of our strategic limited partners and leading academic centers around the country. At the end of 2019, we announced the formation of FSV, whereby we earmarked up to 1.0% of our funds to support Flare Scholar-sponsored opportunities. To date, we have made 34 FSV investments, which collectively have raised a total of $147.0 million as compared to our initial investment of $3.6 million. Subsequent to our initial pre-seed investment, we have invested an additional $12.1 million in three of the FSV companies (Cascala Health, Ounce, Visana Health) as they continue to quickly scale.

We are excited to have recently co-led Cascala’s $8.6 million Seed round, marking the third time we have partnered with CEO and Co-Founder, Matt Murphy, himself a Flare Scholar from the great Class of 2017.

Importantly, we will kick off our recruiting efforts for the Class of 2026 Flare Scholars on September 8th and remain excited about the FSV program. Capital will always follow great talent and in this market, it will be great talent that wins.

And please join us for our next quarterly Expert Roundtable Series webinar on September 23, 2025, at noon ET. And subscribe here to follow other news and insights from Flare Capital Partners.

Leave a comment

Filed under Uncategorized

Healthcare Technology: A Midsummer Night’s Dream…

Wow…that was a poke in the eye. Perhaps not surprisingly, given the new Administration’s dramatic reset of the global economy over the last several months, the impact on employment is just now revealing itself. The revision in preliminary employment data punctured any notion that the extraordinary tariffs would not hit payrolls. Essentially, since Liberation Day in early April job growth has been nominal, bumping up the unemployment rate to 4.2%. Another gem buried in the data: 1.8 million people have now been unemployed for at least six months, the highest since 2017. These headwinds are likely to be made more blustery as automation and AI solutions are broadly deployed.

Nonfarm Payroll Data

Source: Bureau of Labor Statistics; Axios

Notwithstanding the resurgent investment pace in healthcare technology and the focus on automation, the size of the healthcare workforce has been quite resilient. According to the National Center for Health Workforce Analysis report in 2024, there are nearly 18 million healthcare employees in the U.S.; 933k were physicians. Over the course of the year there are an estimated 1.9 million new job openings in the healthcare industry. A recent analysis based on the Bureau of Labor Statistics (BLS) Quarterly Census of Employment and Wages by the New York Times estimated that approximately 13% of the U.S. workforce is in healthcare. Since 1980, average wages in healthcare increased by 60%, meaningfully outstripping the 34% increase in average wages for all other industries.

It is too expedient to simply say that technology will replace labor in healthcare. According to the BLS, the healthcare sector added just under 80k new jobs each month in 2024, which only modestly declined to ~72k new jobs for the last three months as the impact of tariffs started to be felt. Relative to many other industries, particularly the federal government which was adding 4k new jobs monthly in 2024 and is now shedding 16k positions monthly, the healthcare sector continues to be very labor intensive.

Net Monthly Job Creation by Industry (2024 vs. May – July 2025)

Source: Bureau of Labor Statistics; Axios

In addition to being both labor intensive and expensive, the healthcare sector has struggled with improving productivity. Not surprisingly, there is a correlation between the level of education (how facile employees are with AI technologies) and growth in productivity. For the several years between 2019 and 2024, healthcare demonstrated approximately a 20% “AI Use Prevalence” score coupled with an estimated 7% growth in productivity (just over 1% per annum). Surprisingly, this performance lagged several other capital intensive industries.

Industry Productivity as Function of AI Use Prevalence

Source: Federal Reserve Bank of St. Louis, Bureau of Labor Statistics

Given the seductive market opportunity to drive greater operating efficiencies through the broader deployment of automation and AI in healthcare, it is not surprising to see the strength in new investment activity in the healthcare technology sector this past quarter. According to Rock Health,  $3.4 billion was invested in 123 companies in 2Q25, putting the sector on pace for ~$14 billion this year. This would be comfortably greater than the levels seen in 2023 and 2024, and closer to the $15.8 billion of 2022 which was coming off the “Covid high.”

Digital Health Investment Activity

Source: Rock Health

More importantly, nearly 62% of all funding in 1H25 was in AI-enabled companies. The average round size for these companies was $34.4 million as compared to $18.8 million for non-AI companies in the sector. Notably, the three most active areas in 1H25 were non-clinical workflow ($1.9 billion), clinical workflow ($1.9 billion), and data infrastructure ($893 million), underscoring the intense investor focus on automation and AI. Expect to see greater investor attention paid to more effective and earlier interventions as workflows improve, coupled with increased emphasis on better care protocols as AI helps to determine the most appropriate treatment pathways.

Obviously, the volatility (and chaos) in changes to regulatory frameworks is creating significant uncertainty for the path forward (will the government cover GLP-1 drugs for Medicare, Medicaid members; most favored nation pricing; spike in anti-vaccine, anti-science sentiment, etc). Notwithstanding the dramatic cuts to Medicaid and other social safety nets, the enormity of annual healthcare expenditures continues to attract entrepreneurs who seek to drive efficiencies through automation in how care is delivered.

Additionally, the nearly 30% increase in healthcare costs borne by the federal government since the onset of Covid makes the situation simply untenable. Since February 2020, overall federal spending has increased by 25% or $1.4 trillion on a trailing twelve-month basis, one-third of which is the increase in interest expense.

Federal Government Expenditures

Source: U.S. Department of Treasury; Bureau of Labor Statistics

The situation is made even worse when looking at the hostile anti-immigrant stance of the new Administration. According to a recent Kaiser Family Foundation (KFF) analysis, 16% of the hospital workforce is immigrant labor, with California, Florida, New York, and Texas registering greater than 20%. Nearly 70% of immigrant hospital workers are women and 27% of all hospital physicians are immigrants. According to the National Foundation of American Policy, the overall foreign-born workforce in the U.S. has decline by one million since the Inauguration. Conditions coming out of the pandemic are already challenging but the crackdown on immigrant labor coupled with the impact of the One Big Beautiful Bill cuts to Medicaid and other healthcare services will be especially tough.

Share of Hospital Immigrant Labor

Source: KFF, Axios

Through all this turmoil there is one confounding development: the congressional districts most dependent on Medicaid and other social services are predominantly Republican. As of 2023, 56 of the 100 lowest income districts are red. Since 2009 the percentage of voters in the bottom one-third of districts by income that voted Republican has doubled to 37%. Given that many of these budget cuts are not effective until just after the 2026 midterm elections, it is possible that the impact will not be quickly understood. Expect there to be fireworks once that is revealed.

Congressional Districts by Party, by Income

Source: Census Bureau

Speaking of fireworks, there were nearly 15k knuckleheads with fireworks injuries who ended up in emergency rooms across the country this past year, a greater than 50% increase over 2023. Not surprisingly, most of the injuries occur around the July 4th holiday.

Annual Fireworks Injuries

Source: Consumer Product Safety Commission

Be safe out there…

And please join us for our next quarterly Expert Roundtable Series webinar on September 23, 2025, at noon ET. And subscribe here to follow other news and insights from Flare Capital Partners.

Leave a comment

Filed under Uncategorized

Pins and Needles: Venture Capital Landscape…

The state of the capital markets is baffling with conflicting signals issued every day. The stock market is ripping, but 1Q25 GDP growth was just revised downward from a -0.2% to -0.5%.

At first glance last week’s unemployment data looked quite strong with 147k new jobs added overall, but disturbingly most of that increase was for state and local jobs as the private sector was particularly weak with only half of the number of jobs added in May. The juxtaposition of the passing of the “Big Beautiful Bill” was notable. Perhaps these data are an indication that states will now need to pick up what the federal government is abandoning. Another flashing yellow – 130k people quit the labor force.

The public equity performance for the trailing twelve months has largely been running in place, certainly given the expectations attached to the incoming Administration. Notably, the Russell 2000 Index has significantly underperformed the other popular equity indices since the start of 2025, down 2.5% when the S&P 500 Index has increased 5.7%, arguably reflecting investor concerns about the greater exposure small to mid-size companies have to the Administration’s policies.

Performance of Public Stock Indices

Source: Goldman Sachs

It is estimated that the value of all stocks globally totals $115 trillion. The last two decades has witnessed an extraordinary de-leveraging of Corporate America, goosed along by the surging stock market. Interestingly, the relative level of corporate debt today is at near-historic lows, while the level of federal debt is unprecedented. S&P 500 debt to market capitalization is now near 10%, while federal debt to GDP is converging on 100%, likely made worse by the Big Beautiful Bill. A corner of the market showing explosive growth is private credit worth now over $1.7 trillion and is estimated to grow to be as much as $40 trillion. As a point of comparison, hedge funds currently manage approximately $4.5 trillion, according to a recent survey by Barron’s.

Relative Debt Levels (light blue line => left hand axis)

Source: Federal Reserve Bank of St. Louis

The number of public companies in the U.S. has collapsed to approximately 4,300, down from over 8,000 30 years ago. While the reasons for this are numerous (Sarbanes-Oxley, etc), the net effect is that more capital is increasingly invested in companies that sidestep rigorous SEC scrutiny and oversight. The SEC estimates that there are now over 100k privately managed funds. Into this slipstream has stepped the crypto industry which now totals $3.4 trillion in assets, of which $2.1 trillion is in Bitcoin.

According to the National Venture Capital Association, there are nearly 3,400 venture capital firms managing an estimated $1.2 trillion in assets. Private equity funds now control over 12,400 companies as of 1Q25, according to Pitchbook, and are estimated to have $668 billion invested in “tail-end funds” (i.e., older than ten years), according to Treo Asset Management. Unfortunately, Treo goes on to report that one-third of those long-lived assets are worth less than invested capital.

In an era of unprecedented discovery and innovation across every sector of the economy, the global transformation is head-spinning. To illustrate that, Banc of America recently profiled several phenomena: (i) there are 31 satellites right now tracking your exact location; (ii) the amount of food required over the next 40 years will be more than the last 8,000; (iii) given current wireless network speeds, it would take 300 million years to download the entire internet; (iv) enough plastic has been produced to shrink wrap the entire globe; and, (v) and there have been 108 billion people since the dawn of civilization.

This is just a sampling of the potential opportunities, but also the extraordinary challenges we now face. And the pace of change is accelerating which would ordinarily argue for greater oversight with robust guardrails, and yet we are now moving to further deregulate and, in fact, “de-oversight” important sectors of the economy. And it certainly appears that with innovation, population growth surges. The increased population puts additional pressure on the earth’s resources.

Profound Innovation at an Accelerating Pace

Source: BofA Global Economic Research

An obvious and deeply controversial element to population growth is the concomitant migration that is unleashed. The U.S. has gone rail-to-rail on immigration policy and has struggled mightily to find the appropriate balance. As long-held fundamental rights and traditions are being “redefined” (or ignored all together), there are now real concerns about securing adequate labor across many industries.

The innovation economy (and venture capital industry) is quite dependent on skilled immigrant founders and employees who are both technical (i.e., best and brightest from around the world) and entrepreneurial. Obviously, the fear of arrest, fewer visas being issued, and deportations has generated an outflow of “unauthorized” migrants from the country.

Net Immigration to the U.S.

Source: Oxford Economics, Cato Institute

Perhaps in response to these developments, according to Pitchbook’s “First Look” report the venture capital investment activity in 2Q25 showed a marked slowdown in both dollars invested and number of deals with $69.9 billion and 3,038, respectively, when compared to 1Q25 activity of $92.9 billion and 3,622 deals. The Venture Growth stage had the largest decline from $53.2 billion invested in 1Q25 to $30.7 billion in 2Q25. In general, quarterly deal count has continued its descent since the highwater mark of mid-2021, while the capital invested has continued its climb back to mid-2021 levels, driven in large measure by “mega” AI financings.

Quarterly Venture Capital Investment Activity

Source: NVCA, Pitchbook

The bar to raise successful follow-on rounds appears to have been set higher. A study by Carta of over 11k seeded companies between 2017 – 2023 showed that only 17% of them were able to raise a proper Series A within two years of initial funding. This historically has ranged between 30% – 35%. This may, in part, be explained by the fact that median Seed round sizes have increased from $1.5 million in 2017 to $2.8 million in 2023, and this year is running at $3.6 million. Over that same period, the median size of Series A financings nearly doubled from $5.1 million to $10.0 million.

The increase in round sizes is also reflected in the significant increase in pre-money valuations across every round. A comparison of 2019 and year-to-date 2025 data (pre- versus post-Covid) is quite revealing. Median pre-money valuations for Seed and Series A financings in 2019 were $6.6 million and $15.5 million, and $20.0 million and $45.5 million in 2025, respectively. Valuations for Venture Growth rounds increased from $350. 0 million to $900.0 million over that same period.

A straight line can be drawn from this phenomenon and the explosion of AI deals. Of the $69.9 billion invested in 2Q25, $40.5 billion was invested in AI companies, representing 58% of the amount invested yet only 35% of the deals announced. In 2019, pre-Covid, those amounts were 22% and 19%, respectively. In 2Q25 the average round size for an AI investment was $38 million as compared to $15 million for all other deals.

Should we be concerned? Perhaps. Notwithstanding that capital concentration is rarely a good thing (too much, too fast), according to a recent IBM survey of global CEOs, only 25% determined that recent AI investments (products created by all these start-ups) have hit expected ROI thresholds. And yet, 85% of those same CEOs still expect a positive ROI by 2027 through cost-cutting and something called “AI efficiencies.”

Another disconnect: a late 2024 Gallup poll revealed that only 15% of U.S. employees feel that their employer has stated a clear AI strategy.  Notwithstanding that McKinsey research concluded that 88% of enterprises are “undertaking an AI transformation,” only 5% reported having successfully transformed a single business domain.

Liquidity can cover many mistakes. Exit activity in 2Q25 was an encouraging $67.7 billion across 319 transactions, according to Pitchbook. This compared quite favorably to $52.4 billion and 330 transactions, and $38.6 billion and 301 transactions, in 1Q25 and 2Q24, respectively.

The Achilles’ heel to the venture capital model recently has been the abysmal lack of distributions. According to Carta, only 30% of all 2020 vintage year venture capital funds have ANY distributions (70% have yet to distribute a penny by year five). A measly 54% of 2018 funds, which are now seven plus years old, have made a distribution, while 19% of the 2017 funds have yet to do so. Carta calculates that the 2017 vintage year funds have a median IRR of 11.5% as of 1Q25 with a total TVPI (total value to paid-in capital) of 1.72x, yet a DPI (distributed to paid-in capital) of 0.27x, underscoring the extreme level of unrealized gains sitting at many venture capital funds. 

 Percent of Funds with Any Distributions by Vintage Year

Source: Carta

Venture capital investment certainly is a long game. According to an analysis by Silicon Valley Bank, top quartile funds tend to return total committed capital by Year 10 and will likely require an additional five to ten years for the fund to be fully distributed. Obviously, those timelines can be influenced profoundly by moments of investor euphoria or despair.

Median Distributions and Unrealized Gains for Top Quartile Funds

Source: Silicon Valley Bank

A legitimate concern among limited partners is that after the ten-year mark, remaining assets may be liquidated at significant discounts given pressure to wind up the funds as investment managers look to raise a successor fund. A recent study by Institutional Investor reported that there is now more than $3 trillion of unrealized value tied up in venture-backed “unicorns.”  Several recent venture-backed IPOs were priced below the last private round valuation, suggesting that not all the unrealized gains will be captured at the current carrying values.

There is a glimmer of hope for long-standing employees of some of these mature venture-backed companies. With the increased sophistication of the secondary markets, some of these companies are considering tender offers for employees, acknowledging that the average pre-IPO journey is now 12 years. According to a recent Morgan Stanley survey of 150 companies, nearly 40% expected that the next liquidity event would be a private tender offer versus an IPO.

In 2Q25 there were 151 venture capital funds raised totaling $16.6 billion (average fund size $110 million). This was a notable improvement over 1Q25 when 87 funds totaling $10.0 billion were raised. The highwater mark for fundraising was in 2022 when 1,737 funds raised $198.0 billion. Obviously, raising new funds is largely a function of both relative and absolute performance, but also that limited partners expect predictable liquidity from earlier funds. The “false flag” signal in 2022 when venture capital funds distributed nearly one-third of net asset value clearly spurred on significant new fund formation, cheered on by rabid AI enthusiasts.

Venture Funds Trailing 12-Month Distributions as Percent of Net Asset Value

Source: Pitchbook

There are two other developments worth watching when it comes to fundraising:

  • Private Investments in 401(k)s: BlackRock announced last month that it plans to offer target-date funds for individuals that will have between 5% – 20% allocations to private investments. Opening up the private markets to individual investors should drive dramatic inflows to private equity and venture capital funds.
  • Weakening of the U.S. Dollar: Maybe a non-event but the dollar lost 10% of its value so far this year, the worst performance since 1973, in large measure due to bloviating about tariffs and a weakening U.S. economy. As capital rotates away from the U.S., will large international investors shun the venture capital industry, given the lack of liquidity and the Administration’s frontal assault on innovation.

The 2Q25 best performing asset was platinum, up 32.1%, followed closely by the oxymoronic “lean hogs,” which sprinted ahead 25.5%. Given all that we are living through now, it was surprising to see that the worst performing commodity was coffee, which declined 19.2% in the quarter. Just another reason for insomnia.

And please join us for our next quarterly Expert Roundtable Series webinar on September 23, 2025, at noon ET. And subscribe here to follow other news and insights from Flare Capital Partners.

3 Comments

Filed under Uncategorized

European Venture Capital Scene: Spotlight on Italy…

Last week while traveling in Italy the rightwing government codified into law severe restrictions limiting the eligibility requirements for Americans looking to secure Italian passports. How rich is it that given Italy struggles with the most acute population decline in Europe? About 25% of the 59 million Italians are over 65 years old. It is estimated that there are between 16 – 20 million Americans of Italian heritage, many now outraged as they sought possible escape routes back to Italy.

According to Italy’s Foreign Minister, the number of Italians living abroad increased 40% to 6.4 million over the past decade, which is now potentially going to reverse as many look for refuge. More than 191k Italians left just in 2024. The juxtaposition of an American Pope holding his first mass last week in Rome, extolling the virtues of immigration, was prophetic.

Obviously, the global chaos brought on by the new U.S. administration is very evident in Europe. While the distance from Rome to Kyiv is just over 1,000 miles, the war felt much closer. In addition to the movement of people, capital is in flight. The U.S. stock market has consistently and comfortably out-performed European indices, nearly doubling in returns over the past dozen plus years, but that has not been the case for the past several months.

Comparison of European and U.S. Stock Indices

Source: Morningstar (May 2025)

In addition to a dramatic weakening of the U.S. dollar, which has declined nearly 8% since the start of 2025, U.S. benchmark equity indices have declined. In 1Q25, the Morningstar Europe Index increased 6% while the Morningstar U.S. Market Index dropped 8.5% (in euros). Year-to-date through May the European Index has increased 11% while the U.S. Index has dropped nearly 9%, signaling a profound rotation of capital away from the U.S. The Hang Seng Index in Hong Kong is up a remarkable 19+% year-to-date, while the Japanese Nikkei 225 Index has shed more than 5% of its value.

Global Stock Indices Performance (YTD)

Source: VettaFi Advisor Perspectives

While there are undoubtedly numerous contributing factors to account for the bubble chart below, the inability to consistently access sufficient capital on reasonable terms must play a role. The juxtaposition of the U.S. and Europe when comparing scaled companies is stark and profound. There is not one scaled European start-up in the past 50 years to eclipse $100 billion in market value, while there are six companies worth more than $1 trillion each in the U.S. over that same period. There are thirteen scaled start-ups in Europe worth more than $10 billion with an aggregate value of ~$400 billion. All the scaled U.S. start-ups valued at over $10 billion total more than $30 trillion in value or 70x those in Europe.  

Number of Start-Ups to Scale to $10+ Billion of Market Capitalization

Source: Andrew McAfee, Wall Street Journal

The situation is just as acute when looking only at private technology companies. There are only 107 such companies in Europe and they are valued at $333 billion, according to an analysis by the Wall Street Journal, as compared to 690 companies worth $2.5+ trillion in the U.S. Globally, only four of the top 50 technology companies are based in Europe. The lack of scaled technology start-ups reflects, in part, the patch work nature of regulations and standards across Europe.

Number of Private Technology Companies Valued at $1.0+ Billion

Source: CB Insights, Wall Street Journal

According to the International Monetary Fund, 1985 is the average year of the founding of the top 10 public U.S. companies, while in Europe it is 1911, further underscoring the sclerotic nature of Corporate Europe. Furthermore, over the past 25 years the hourly industrial output of the European worker declined from 95% of that of the U.S. employee to 80%.

Notwithstanding this landscape, the private equity and venture capital sectors have seen a recent modest renaissance in Europe. While still a small fraction of the investment activity in the U.S. ($209 billion was invested in 2024 alone), total European venture capital investment activity tends to run about only 20% annually of that in the U.S. Recent tariff headwinds, regional differences by country, and the absence of a mature and well-heeled venture capital industry has not served Europe well. The United Kingdom continues to play a leadership role while Italy ranks tenth of the 44 countries with capital cities on the European continent.  

Venture Capital Investment by Country (2023-2024)

Source: Dealroom.co

According to an analysis by Gianni & Origoni, an international law firm, €8.6 billion has been invested over the past decade in Italian start-ups, with €1.1 billion invested in 628 companies just in 2024. Much of this momentum has been attributed to a concerted and coordinated effort to develop a more robust entrepreneurial ecosystem.  Notably, Italy passed the Competition Law of December 2024 several months ago which instituted a tax exemption on capital gains from venture capital investments for pension funds with 5% of their overall portfolio being in venture capital, stepping up to 10% in 2026.

Graduation Rate to Next Round of Venture Capital

Source: Dealroom.co

Perhaps not surprisingly, Italian venture capitalists have tended to focus on “hard” advanced technologies grounded in substantive academic research and are less focused on consumer-centric sectors such as advertising, ecommerce, and media.

Italian Venture Capital Investment by Sector (2024)

Source: Dealroom.co

The size of financing rounds also reflects the developing nature of the European venture capital sector and stand in stark contrast to the U.S. The median round size for all rounds before Venture Growth rounds is single digit million euros, according to Pitchbook. For context, the 2024 average round size for Early-Stage U.S. venture capital financings was $10.1 million as compared to the median European Early-Stage financing of €1.8 million (~$2.0 million). Notably, round sizes in 1Q25 across all stages have increased over 2024 levels.

Median Round Size by Stage

Source: Pitchbook

Other than for the Venture Growth stage, valuations across the board have largely stayed flat in 1Q25 when compared to 2024, perhaps reflecting some investor risk aversion. The median pre-money valuation for European Early-Stage rounds in 1Q25 was €6.2 billion, suggesting investors acquired ~23% of the companies in those financings (amount of founder dilution is closely monitored). The median pre-money valuation for U.S. Early-Stage companies in 2024 was $47.6 million, which is more in line with the €44.5 million for European Venture Growth stage companies – two subsequent rounds later.

Median Pre-Money Valuations by Stage

Source: Pitchbook

There was one other notable demographic announcement by the Italian government last week. Italy’s constitutional court reaffirmed the ban on single women from having in vitro fertilization (IVF) given that they are not a “traditional” family. This flies in the face of Prime Minister Meloni’s stated concerns about an aging and shrinking population, herself raised by a single mother. Importantly, and in a separate but related ruling, that same court codified that women in a same-sex relationship can both be recognized as the parents in an IVF procedure. Go figure.

And please join us for our next quarterly Expert Roundtable Series webinar on June 10, 2025, at noon ET. And subscribe here to follow other news and insights from Flare Capital Partners.

Leave a comment

Filed under Uncategorized